Seres Therapeutics, Inc. (MCRB)
Pre-market:
| Previous close | 6.09 |
| Open | 6.10 |
| Bid | 6.10 x 900 |
| Ask | 6.40 x 800 |
| Day's range | 5.84 - 6.17 |
| 52-week range | 2.50 - 9.49 |
| Volume | |
| Avg. volume | 880,983 |
| Market cap | 738.805M |
| Beta (5Y monthly) | 2.69 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.51 |
| Earnings date | 02 May 2023 - 08 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.00 |
- Zacks
Seres Therapeutics (MCRB) Moves 10.9% Higher: Will This Strength Last?
Seres Therapeutics (MCRB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- Business Wire
Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
CAMBRIDGE, Mass., March 09, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will provide a corporate presentation at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 2023 at 8:40 a.m. ET.
- Zacks
Seres Therapeutics (MCRB) Reports Q4 Loss, Misses Revenue Estimates
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -31.71% and 89.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
